{"id":11144,"date":"2022-09-17T00:00:00","date_gmt":"2022-09-17T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/lisatuximab-apporte-un-benefice-de-survie-globale-cliniquement-significatif-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais-seulement\/"},"modified":"2025-08-19T08:28:14","modified_gmt":"2025-08-19T13:28:14","slug":"lisatuximab-apporte-un-benefice-de-survie-globale-cliniquement-significatif-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais-seulement","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2022\/09\/17\/lisatuximab-apporte-un-benefice-de-survie-globale-cliniquement-significatif-dans-les-cas-de-myelome-multiple-recidivant-refractaire-en-anglais-seulement\/","title":{"rendered":"L\u2019ISATUXIMAB APPORTE UN B\u00c9N\u00c9FICE DE SURVIE GLOBALE \u00ab CLINIQUEMENT SIGNIFICATIF \u00bb DANS LES CAS DE MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT-R\u00c9FRACTAIRE (EN ANGLAIS SEULEMENT)"},"content":{"rendered":"<p>Isatuximab provides a clinically meaningful benefit in overall survival (OS) when added to pomalidomide and low-dose dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (MM), according to researchers.&nbsp;<\/p>\n<p>Lire la suite <a href=\"https:\/\/www.cancertherapyadvisor.com\/home\/cancer-topics\/multiple-myeloma\/isatuximab-provides-clinically-meaningful-os-benefit-in-rel-ref-multiple-myeloma\/#:~:text=September%202%2C%202022-,Isatuximab%20Provides%20%E2%80%9CClinically%20Meaningful%E2%80%9D%20OS%20Benefit,in%20Rel%2FRef%20Multiple%20Myeloma&amp;text=Isatuximab%20provides%20a%20clinically%20meaningful,MM)%2C%20according%20to%20researchers.\" target=\"_blank\" rel=\"noopener\">ici<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Isatuximab provides a clinically meaningful benefit in overall survival (OS) when added to pomalidomide and low-dose dexamethasone (Pd) in patients with relapsed\/refractory multiple myeloma (MM), according to researchers.&nbsp; Lire la suite ici.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11144","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11144"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11144\/revisions"}],"predecessor-version":[{"id":31279,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11144\/revisions\/31279"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}